Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: SI-Bone (SIBN), Pliant Therapeutics (PLRX) and Steris (STE)

Tipranks - Tipranks - Wed May 13, 6:20AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on SI-Bone (SIBN), Pliant Therapeutics (PLRX) and Steris (STE).

Claim 55% Off TipRanks

SI-Bone (SIBN)

Needham analyst David Saxon reiterated a Buy rating on SI-Bone today and set a price target of $27.00. The company’s shares closed last Monday at $11.61.

According to TipRanks.com, Saxon has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -2.9% and a 31.4% success rate. Saxon covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, Irhythm Technologies, and Alphatec Holdings. ;'>

Currently, the analyst consensus on SI-Bone is a Strong Buy with an average price target of $23.17, implying an 87.3% upside from current levels. In a report released yesterday, Morgan Stanley also assigned a Buy rating to the stock with a $18.00 price target.

See today’s best-performing stocks on TipRanks >>

Pliant Therapeutics (PLRX)

In a report released today, Joseph Stringer from Needham maintained a Hold rating on Pliant Therapeutics. The company’s shares closed last Monday at $1.20.

According to TipRanks.com, Stringer is a 5-star analyst with an average return of 24.5% and a 47.4% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Phathom Pharmaceuticals, and Vertex Pharmaceuticals. ;'>

Pliant Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $2.67, which is an 118.9% upside from current levels. In a report issued on April 28, TipRanks – xAI also reiterated a Hold rating on the stock with a $1.00 price target.

Steris (STE)

Needham analyst Michael Matson maintained a Hold rating on Steris today. The company’s shares closed last Monday at $201.85, close to its 52-week low of $197.82.

According to TipRanks.com, Matson is a 2-star analyst with an average return of 0.0% and a 41.8% success rate. Matson covers the Healthcare sector, focusing on stocks such as Insight Molecular Diagnostics, Establishment Labs Holdings, and Zimmer Biomet Holdings. ;'>

Currently, the analyst consensus on Steris is a Moderate Buy with an average price target of $300.00, a 45.7% upside from current levels. In a report issued on April 28, TipRanks – xAI also downgraded the stock to Hold with a $235.00 price target.

Read More on SIBN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).